Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Methylene blue as an antimalarial agent.

R Heiner Schirmer1, Boubacar Coulibaly, August Stich

  • 1Biochemistry Center, Heidelberg University, Heidelberg Germany. heiner.schirmer@gmx.de

Redox Report : Communications in Free Radical Research
|February 14, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Inequalities and determinants of unmet need for SARS-CoV-2 testing in Ghana, Burkina Faso and Madagascar (2020 - 2021).

Communications medicine·2026
Same author

Erratum to "Serum perfluoroalkyl substances and infant measles antibody concentrations before and after vaccination: Results from Burkina Faso" [Environ. Toxicol. Pharmacol. 124 (2026) 104979].

Environmental toxicology and pharmacology·2026
Same author

Baseline Procalcitonin and C-Reactive Protein Levels in Asymptomatic Individuals From West Africa With and Without <i>P. falciparum</i> Parasitemia.

Open forum infectious diseases·2026
Same author

Serum perfluoroalkyl substances and infant measles antibody concentrations before and after vaccination: Results from Burkina Faso.

Environmental toxicology and pharmacology·2026
Same author

A rare complication in humans of a rare disease in Germany: a case of bilateral tubo-ovarian abscesses caused by Brucella melitensis.

Infection·2026
Same author

Exploring heterogeneity in treatment effects: The impact and interaction of asset-based wealth and mass azithromycin distribution on child mortality.

PloS one·2026

Methylene blue shows antimalarial effects and enhances chloroquine efficacy by inhibiting parasite glutathione reductase. This combination, BlueCQ, is being studied for malaria treatment in endemic areas.

Area of Science:

  • Tropical Medicine
  • Parasitology
  • Pharmacology

Background:

  • Methylene blue possesses inherent antimalarial properties.
  • It acts as a sensitizer for chloroquine, an established antimalarial drug.
  • Methylene blue can also prevent methemoglobinemia, a severe complication in malarial anemia.

Purpose of the Study:

  • To investigate the antimalarial activity of methylene blue as a chloroquine sensitizer.
  • To evaluate the combination therapy of chloroquine with methylene blue (BlueCQ) for malaria treatment.
  • To explore the potential of BlueCQ in malaria-endemic regions.

Main Methods:

  • Studying the antiparasitic mechanisms of methylene blue, including its effects on hemoglobin and heme metabolism.
  • Identifying methylene blue as a selective inhibitor of Plasmodium falciparum glutathione reductase.

Related Experiment Videos

  • Conducting a pilot study of BlueCQ in glucose-6-phosphate dehydrogenase-sufficient adult patients in Burkina Faso.

    • Main Results:

    • Methylene blue interferes with Plasmodium falciparum's hemoglobin and heme metabolism.
    • It selectively inhibits Plasmodium falciparum glutathione reductase, leading to glutathione depletion.
    • Glutathione depletion sensitizes the malaria parasite to chloroquine.

    Conclusions:

    • Methylene blue demonstrates pleiotropic antiparasitic activity against malaria parasites.
    • The combination of chloroquine with methylene blue (BlueCQ) shows promise for malaria treatment.
    • Further studies are warranted to establish BlueCQ as a viable therapeutic option in endemic areas.